newer cancer therapies immunotherapy angiotherapy gene therapy
TRANSCRIPT
![Page 1: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/1.jpg)
Newer cancer therapiesNewer cancer therapies
ImmunotherapyImmunotherapyAngiotherapy Angiotherapy Gene therapyGene therapy
![Page 2: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/2.jpg)
ImmunotherapyImmunotherapy
![Page 3: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/3.jpg)
ImmunotherapyImmunotherapy
![Page 4: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/4.jpg)
ImmunotherapyImmunotherapy Non-specific immunotherapyNon-specific immunotherapy
BCG BCG CytokinesCytokines Cell therapyCell therapy
Specific immunotherapySpecific immunotherapy adoptive adoptive
Antibody therapyAntibody therapy Adoptive transfer of T cellsAdoptive transfer of T cells
VaccinationVaccination Tumour-based vaccinesTumour-based vaccines Virus-based vaccinesVirus-based vaccines Peptide-based vaccinesPeptide-based vaccines othersothers
![Page 5: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/5.jpg)
ImmunotherapyImmunotherapy
![Page 6: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/6.jpg)
ImmunotherapyImmunotherapy
![Page 7: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/7.jpg)
ImmunotherapyImmunotherapy
![Page 8: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/8.jpg)
AngiotherapyAngiotherapy
![Page 9: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/9.jpg)
Key differences in tumour Key differences in tumour vasculaturevasculature
Different flow Different flow characteristics / characteristics / blood volumeblood volume
Microvasculature Microvasculature permeabilitypermeability
Increased Increased fractional fractional volume of volume of extravascular, extravascular, extracellular extracellular spacespace
![Page 10: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/10.jpg)
Angiogenesis-overviewAngiogenesis-overview Balance between inhibitory factors (endostatin) and angiogenic factors (VEGF, bFGF)
angiogenic factors stimulate MMPs and plasminogen activators
Degradation of basement membrane
Invasion and differentiation of endothelial cells in surrounding tissues
![Page 11: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/11.jpg)
![Page 12: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/12.jpg)
Before treatment after treatment
BLOOD FLOW
![Page 13: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/13.jpg)
MMPIsMMPIs
Disappointing results with matrix Disappointing results with matrix metalloproteinase inhibitors metalloproteinase inhibitors
Poor survival rate in phase III clinical trials Poor survival rate in phase III clinical trials against renal cell carcinomaagainst renal cell carcinoma
![Page 14: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/14.jpg)
Newer cancer therapiesNewer cancer therapiesGene therapyGene therapy
Severe Combined Immunodeficiency Disease (SCID)
![Page 15: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/15.jpg)
Antisense therapy Antisense therapy (suppress gene expression)(suppress gene expression)
Gene augmentation Gene augmentation (supplement defective gene)(supplement defective gene)
Gene therapyGene therapy
![Page 16: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/16.jpg)
Antisense therapyAntisense therapycompensates for genetic compensates for genetic
mutations that produce mutations that produce destructive proteinsdestructive proteins
Main strategies involved areMain strategies involved are
1) short stretches of synthetic 1) short stretches of synthetic DNA that target the mRNA DNA that target the mRNA transcripts of abnormal transcripts of abnormal proteins preventing its proteins preventing its translation ORtranslation OR
small RNA molecules small RNA molecules (siRNA) used to degrade (siRNA) used to degrade aberrant RNA transcriptsaberrant RNA transcripts
![Page 17: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/17.jpg)
Antisense therapyAntisense therapy
2) provide a gene for a 2) provide a gene for a protein (intracellular protein (intracellular antibody) that can antibody) that can block the activity of the block the activity of the mutant proteinmutant protein
Tumor necrosis therapy utilizes monoclonal antibodies targeting intracellular tumor antigens on necrotic (dead) tissue. This method overcomes some of the limitations of current antibody-based therapeutic approaches
3)3) design hybrids of design hybrids of DNA / RNA that DNA / RNA that might direct repair of might direct repair of the mutant gene the mutant gene
![Page 18: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/18.jpg)
Gene augmentationGene augmentationmost therapies simply add a useful gene into a most therapies simply add a useful gene into a
selected cell type to compensate for the missing or selected cell type to compensate for the missing or flawed version or even instil an entirely new flawed version or even instil an entirely new version. version.
Direct approach Direct approach
inducing cancer cells to make a protein that will kill inducing cancer cells to make a protein that will kill the cell. the cell.
Indirect approach Indirect approach
stimulating an immune response against selected stimulating an immune response against selected cells or eliminating the blood supply. cells or eliminating the blood supply.
![Page 19: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/19.jpg)
deliverydelivery
3 challenges in gene therapy3 challenges in gene therapy
deliverydelivery deliverydelivery
1)1) Package the genePackage the gene2)2) Protect the geneProtect the gene3)3) deliver to the nucleus and release deliver to the nucleus and release
in an active formin an active form
Vectors ‘Trojan horses’ that sneak the gene into the cell
![Page 20: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/20.jpg)
Carrier molecules designed Carrier molecules designed specifically to enter cells & deposit specifically to enter cells & deposit
therapeutic genestherapeutic genes
Vectors can be viral or non-viral Vectors can be viral or non-viral
VectorsVectors
![Page 21: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/21.jpg)
METHODS OF VECTOR DELIVERYMETHODS OF VECTOR DELIVERY
![Page 22: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/22.jpg)
Viral vector strategyViral vector strategyReplication & virulence genes can be Replication & virulence genes can be
substituted with therapeutic genessubstituted with therapeutic genes
![Page 23: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/23.jpg)
designed to enter cell and deposit genesdesigned to enter cell and deposit genes
Problems Problems of retroviral therapy includeof retroviral therapy include
Lack of cell specificity:Lack of cell specificity: Promiscuous: depositing genes into Promiscuous: depositing genes into several cell types resulting in reduced several cell types resulting in reduced target efficiency and unwanted target efficiency and unwanted physiological effectsphysiological effects
Random splicing into host DNARandom splicing into host DNA resulting in normal gene disruption resulting in normal gene disruption and/or alteration in gene function and/or alteration in gene function
Retroviral vectorsRetroviral vectors
![Page 24: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/24.jpg)
Adenoviral vectorsAdenoviral vectors
do not insert into genome
temporary
lack of specificity
strong immune response
![Page 25: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/25.jpg)
Adeno-associated viral vectorsAdeno-associated viral vectors
Nature Reviews Genetics 1; 91-99 (2000);
Integrate into genome but small in size
![Page 26: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/26.jpg)
AdvantagesAdvantages
non-toxicnon-toxic
no immune responseno immune response
Non-viral VectorsNon-viral Vectors
![Page 27: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/27.jpg)
Tumour-suppressor gene deliveryTumour-suppressor gene delivery
Nature Reviews Cancer (2001) Vol 1; 130-141
![Page 28: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/28.jpg)
Delivery of agents that block Delivery of agents that block oncogene expressiononcogene expression
Nature Reviews Cancer (2001) Vol 1; 130-141
![Page 29: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/29.jpg)
Suicide gene deliverySuicide gene delivery
Nature Reviews Cancer (2001) Vol 1; 130-141
![Page 30: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/30.jpg)
Conditionally replicating virusesConditionally replicating viruses
![Page 31: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/31.jpg)
Non-viral VectorsNon-viral Vectors
liposomes (lipoplexes)liposomes (lipoplexes)
![Page 32: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/32.jpg)
amino acid polymers: cationic polymers amino acid polymers: cationic polymers
e.g. B-cyclodextrinse.g. B-cyclodextrins
Non-viral VectorsNon-viral Vectors
![Page 33: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/33.jpg)
naked DNA naked DNA
artificial human chromosomes artificial human chromosomes
Non-viral VectorsNon-viral Vectors Gene gun
![Page 34: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/34.jpg)
SuccessesSuccesses Cancer and the p53 gene. Researchers used a virus to carry a normal
copy of the p53 gene into the abdominal and pelvic areas of women with advanced ovarian cancer. Seven of 25 women tested in California and Iowa survived more than 2 years after the therapy, despite having a terminal diagnosis.
Cancer and enzyme therapy. This type of therapy targets enzymes, or proteins, that are made by abnormal genes. Example: Gleevec, a new drug, targets an abnormal protein produced by a cancer-causing gene. The abnormal protein is necessary for some types of cancer to survive and reproduce. Gleevec blocks the action of the protein. Gleevec has been successful in chronic myeloid leukemia and in gastrointestinal stromal tumors. It is being tested in other types of cancer.
Cancer and other therapies. Advances in identifying genes have helped researchers to target other therapies. Example: Herceptin targets the HER-2 gene. In 25%-35% of breast cancers, HER-2 produces too many copies of itself, causing breast cancer cells to reproduce out of control and spread throughout the body. Herceptin blocks excess HER-2 by binding to growth receptors on the surface of the cell, causing tumors to shrink.
![Page 35: Newer cancer therapies Immunotherapy Angiotherapy Gene therapy](https://reader035.vdocuments.mx/reader035/viewer/2022062407/56649caf5503460f94973869/html5/thumbnails/35.jpg)
Gleevec for chronic myeloid leukaemia (CML)Gleevec for chronic myeloid leukaemia (CML) CML results through a chromosomal rearrangement that fuses two genes CML results through a chromosomal rearrangement that fuses two genes
together. This produces an oncogene that encodes an enzyme, a form of together. This produces an oncogene that encodes an enzyme, a form of tyrosine kinase known as tyrosine kinase known as BCR-ABL.BCR-ABL. Unchecked production of that enzyme Unchecked production of that enzyme leads to excessive levels of white blood cells in the blood and bone marrow. leads to excessive levels of white blood cells in the blood and bone marrow. that disrupts the normal production of white blood cells. that disrupts the normal production of white blood cells.
Gleevec works specifically to block the activity of that form of tyrosine Gleevec works specifically to block the activity of that form of tyrosine kinase. kinase.